modafinil has been researched along with Disease Models, Animal in 51 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Modafinil, an FDA approved wakefulness drug prescribed to narcolepsy patients, has recently been shown to have anti-inflammatory effects and provides protection against neuroinflammation." | 7.88 | Modafinil attenuates inflammation via inhibiting Akt/NF-κB pathway in apoE-deficient mouse model of atherosclerosis. ( Chen, D; Han, J; Liu, D; Zhu, Y, 2018) |
| "We investigated effects of modafinil on attention and sensorimotor gating after subchronic treatment during a restraint stress protocol inducing depression-like changes in rats." | 7.75 | Depression-like deficits in rats improved by subchronic modafinil. ( Koch, H; Köhler, C; Krügel, U; Preiss, R; Regenthal, R, 2009) |
| "Modafinil plays a role in vasorelaxation and blocking KCa3." | 5.43 | Modafinil improves monocrotaline-induced pulmonary hypertension rat model. ( Cho, MS; Hong, YM; Kim, KC; Lee, H; Suh, SH, 2016) |
| "Modafinil, is a wake-promoting drug approved by Food and Drugs Administration (FDA) for narcolepsy and sleep-apnoe syndrome." | 5.42 | Effects of modafinil on pentylenetetrazol-induced convulsive epilepsy. ( Aydin, D; Ekici, F; Ozsoy, S, 2015) |
| " The objective of this experiment is to investigate the protective effects of modafinil on colitis induced by acetic acid in rat and the involvement of nitric oxide pathway." | 3.96 | Biochemical and histopathological evidence for the beneficial effects of modafinil on the rat model of inflammatory bowel disease: involvement of nitric oxide pathway. ( Dehpour, AR; Dejban, P; Rahimi, N; Takzare, N, 2020) |
| "Modafinil, an FDA approved wakefulness drug prescribed to narcolepsy patients, has recently been shown to have anti-inflammatory effects and provides protection against neuroinflammation." | 3.88 | Modafinil attenuates inflammation via inhibiting Akt/NF-κB pathway in apoE-deficient mouse model of atherosclerosis. ( Chen, D; Han, J; Liu, D; Zhu, Y, 2018) |
| "Treatment with dopaminergic agents result excessive daytime sleepiness (EDS) and some studies have shown the benefit of using modafinil for treating excessive daytime sleepiness of Parkinson's disease (PD) patient." | 3.88 | Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease. ( Ando, R; Choudhury, ME; Kannou, M; Kubo, M; Kyaw, WT; Nagai, M; Nishikawa, N; Nomoto, M; Tanaka, J; Yamanishi, Y, 2018) |
| "Modafinil is a non-amphetaminic wake-promoting compound used as therapy against sleepiness and narcolepsy." | 3.83 | Impact of Astroglial Connexins on Modafinil Pharmacological Properties. ( Charvériat, M; Chauveau, F; Dauvilliers, Y; Duchêne, A; Giaume, C; Jeanson, T; Lagarde, D; Lin, JS; Liu, X; Mouthon, F; Perier, M; Picoli, C; Piérard, C; Thomasson, J; Zhao, Y, 2016) |
| " Then, we combined it with different doses of psychostimulants (d-amphetamine, modafinil, caffeine) to find the best combination for motion sickness." | 3.83 | The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness. ( Han, B; Liu, AJ; Liu, HQ; Song, XR; Tian, JS; Yu, XH; Zhang, LL; Zhang, Y, 2016) |
| "We investigated the hypothesis that modafinil enhances resting ventilation as well as the stimulatory ventilatory responses to hypercapnia and hypoxia." | 3.83 | Disharmony between wake- and respiration-promoting activities: effects of modafinil on ventilatory control in rodents. ( Fukushi, I; Hasebe, Y; Okada, Y; Pokorski, M; Takeda, K; Tatsumi, K; Terada, J, 2016) |
| "The smaller dose of modafinil (32 mg/kg) impaired memory consolidation, without modifying anxiety or locomotion." | 3.81 | Effects of post-training modafinil administration in a discriminative avoidance task in mice. ( Bittencourt, LR; Bizerra, CS; Fernandes, HA; Frussa-Filho, R; Lopes-Silva, LB; Patti, Cde L; Tufik, S; Zanin, KA, 2015) |
| "We evaluated the wake-promoting efficacy of paraxanthine, caffeine, and a reference wake-promoting compound, modafinil, in a mice model of narcolepsy, a prototypical disease model of hypersomnia." | 3.76 | Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. ( Fujiki, N; Ishimaru, Y; Kotorii, N; Nishino, S; Okuro, M; Sokoloff, P, 2010) |
| "We investigated effects of modafinil on attention and sensorimotor gating after subchronic treatment during a restraint stress protocol inducing depression-like changes in rats." | 3.75 | Depression-like deficits in rats improved by subchronic modafinil. ( Koch, H; Köhler, C; Krügel, U; Preiss, R; Regenthal, R, 2009) |
| "The present work was designed to establish a novel animal model for motion sickness (MS) in rodents and to evaluate the effects of a combination of scopolamine and modafinil on MS with this novel method." | 3.74 | A novel animal model for motion sickness and its first application in rodents. ( Cai, GJ; Chu, ZX; Liu, AJ; Su, DF; Yu, XH, 2007) |
| "Excessive daytime sleepiness (EDS) is a common consequence of OSA and is associated with cognitive deficits and anxiety." | 3.30 | Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA. ( Badran, M; Barrow, MB; Gozal, D; Puech, C; Runion, AR, 2023) |
| "Narcolepsy is characterized by excessive daytime sleepiness (EDS), cataplexy, direct onsets of rapid eye movement (REM) sleep from wakefulness (DREMs) and deficiency of orexins, neuropeptides that promote wakefulness largely via activation of histamine (HA) pathways." | 2.73 | An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. ( Anaclet, C; Arnulf, I; Bastuji, H; Dauvilliers, Y; Kocher, L; Lecomte, JM; Lehert, P; Ligneau, X; Lin, JS; Parmentier, R; Perrin, D; Robert, P; Roux, M; Schwartz, JC; Yanagisawa, M, 2008) |
| "Narcolepsy is an emblematic, unique disease within sleep disorders that is characterised by excessive daytime sleepiness, cataplexy and other abnormal manifestations of REM sleep." | 2.48 | [Diagnostic and therapeutic update in narcolepsy]. ( Santamaria-Cano, J, 2012) |
| "Modafinil has been proven to exert anti-inflammatory, anti-oxidative and neuroprotective effects on numerous neurological disorders." | 1.91 | Modafinil attenuates the neuroinflammatory response after experimental traumatic brain injury. ( Bozkurt, I; Cingirt, M; Gulbahar, O; Guvenc, Y; Kepoglu, U; Ozcerezci, T; Ozturk, Y; Senturk, S; Yaman, ME, 2023) |
| "OSA can induce excessive daytime sleepiness (EDS) and is associated with impaired cognition and anxiety." | 1.91 | Recovery Mimicking "Ideal" CPAP Adherence Does Not Improve Wakefulness or Cognition in Chronic Murine Models of OSA: Effect of Wake-Promoting Agents. ( Badran, M; Barrow, MB; Gozal, D; Puech, C; Runion, AR, 2023) |
| " Previously, it has been shown that long-term administration of psychostimulants (Methylphenidate and Modafinil) induced locomotor sensitization effect that was more pronounced after 13 days of drug administration and was greater at high dose." | 1.56 | Repeated restraint stress potentiates methylphenidate and modafinil-induced behavioral sensitization in rats. ( Alam, N; Chaudhary, K, 2020) |
| "Modafinil is a psychostimulant drug prescribed mainly for treatment of narcolepsy but is used as a "smart drug" by wide populations to increase wakefulness, concentration and overall mental performance." | 1.48 | Prenatal exposure to modafinil alters locomotor behaviour and leucocyte phagocytosis in mice. ( Amchova, P; Machalova, A; Pistovcakova, J; Ruda-Kucerova, J; Sulcova, A, 2018) |
| "Modafinil plays a role in vasorelaxation and blocking KCa3." | 1.43 | Modafinil improves monocrotaline-induced pulmonary hypertension rat model. ( Cho, MS; Hong, YM; Kim, KC; Lee, H; Suh, SH, 2016) |
| "Modafinil, is a wake-promoting drug approved by Food and Drugs Administration (FDA) for narcolepsy and sleep-apnoe syndrome." | 1.42 | Effects of modafinil on pentylenetetrazol-induced convulsive epilepsy. ( Aydin, D; Ekici, F; Ozsoy, S, 2015) |
| "Caffeine treatment prevented the SD induced down-regulation of synaptophysin and synapsin I proteins with no change in PSD-95 protein in hippocampus." | 1.42 | Caffeine and modafinil given during 48 h sleep deprivation modulate object recognition memory and synaptic proteins in the hippocampus of the rat. ( Kauser, H; Kumari, P; Panjwani, U; Ray, K; Sahu, S; Wadhwa, M, 2015) |
| "Modafinil is a wake-promoting drug and has been approved for the treatment of excessive daytime sleepiness in narcolepsy and obstructive sleep apnea." | 1.39 | Differential effects of modafinil on memory in naïve and memory-impaired rats. ( Busato, SB; D'avila Portal, BC; Garcia, VA; Piazza, FC; Schröder, N; Souza de Freitas, B, 2013) |
| "Modafinil was efficacious in increasing wheel running in the doxorubicin group." | 1.39 | A clinically translatable mouse model for chemotherapy-related fatigue. ( Fey, EG; Lyng, GD; Sonis, ST; Zombeck, JA, 2013) |
| "Modafinil (Provigil) is a wake-promoting drug characterized by cognitive enhancing abilities." | 1.36 | Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse. ( Reichel, CM; See, RE, 2010) |
| "Glycogenin mRNA levels were increased only after GSD, while neuronal glucose transporter mRNA only after MOD." | 1.36 | Metabolic response of the cerebral cortex following gentle sleep deprivation and modafinil administration. ( Borbély, AA; Kopp, C; Magistretti, PJ; Morgenthaler, F; Petit, JM; Tobler, I, 2010) |
| "Epilepsy is characterized by neuronal hyperexcitability and hypersynchronization." | 1.34 | Modafinil exerts a dose-dependent antiepileptic effect mediated by adrenergic alpha1 and histaminergic H1 receptors in mice. ( Chen, CR; Huang, ZL; Qiu, MH; Qu, WM; Urade, Y; Xu, XH; Yao, MH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 12 (23.53) | 29.6817 |
| 2010's | 29 (56.86) | 24.3611 |
| 2020's | 9 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ozturk, Y | 1 |
| Bozkurt, I | 1 |
| Guvenc, Y | 1 |
| Kepoglu, U | 1 |
| Cingirt, M | 1 |
| Gulbahar, O | 1 |
| Ozcerezci, T | 1 |
| Senturk, S | 1 |
| Yaman, ME | 1 |
| Badran, M | 2 |
| Puech, C | 2 |
| Barrow, MB | 2 |
| Runion, AR | 2 |
| Gozal, D | 2 |
| Yousefi-Manesh, H | 1 |
| Rashidian, A | 1 |
| Hemmati, S | 1 |
| Shirooie, S | 1 |
| Sadeghi, MA | 1 |
| Zarei, N | 1 |
| Dehpour, AR | 2 |
| Alam, N | 1 |
| Chaudhary, K | 1 |
| Dejban, P | 1 |
| Rahimi, N | 1 |
| Takzare, N | 1 |
| Vas, S | 1 |
| Casey, JM | 1 |
| Schneider, WT | 1 |
| Kalmar, L | 1 |
| Morton, AJ | 2 |
| Nazarian, S | 1 |
| Abdolmaleki, Z | 1 |
| Torfeh, A | 1 |
| Shirazi Beheshtiha, SH | 1 |
| Zager, A | 1 |
| Brandão, WN | 1 |
| Margatho, RO | 1 |
| Peron, JP | 1 |
| Tufik, S | 4 |
| Andersen, ML | 1 |
| Kornum, BR | 1 |
| Palermo-Neto, J | 1 |
| Han, J | 1 |
| Chen, D | 1 |
| Liu, D | 1 |
| Zhu, Y | 1 |
| Ando, R | 1 |
| Choudhury, ME | 1 |
| Yamanishi, Y | 1 |
| Kyaw, WT | 1 |
| Kubo, M | 1 |
| Kannou, M | 1 |
| Nishikawa, N | 1 |
| Tanaka, J | 1 |
| Nomoto, M | 1 |
| Nagai, M | 1 |
| Ruda-Kucerova, J | 1 |
| Amchova, P | 1 |
| Machalova, A | 1 |
| Pistovcakova, J | 1 |
| Sulcova, A | 1 |
| Nilsson, SRO | 1 |
| Heath, CJ | 1 |
| Takillah, S | 1 |
| Didienne, S | 1 |
| Fejgin, K | 1 |
| Nielsen, V | 1 |
| Nielsen, J | 1 |
| Saksida, LM | 1 |
| Mariani, J | 1 |
| Faure, P | 1 |
| Didriksen, M | 1 |
| Robbins, TW | 2 |
| Bussey, TJ | 1 |
| Mar, AC | 1 |
| Dias, VT | 1 |
| Rosa, HZ | 1 |
| D'avila, LF | 1 |
| Vey, LT | 1 |
| Barcelos, RCS | 1 |
| Burger, ME | 1 |
| González, B | 1 |
| Bernardi, A | 1 |
| Torres, OV | 1 |
| Jayanthi, S | 1 |
| Gomez, N | 1 |
| Sosa, MH | 1 |
| García-Rill, E | 3 |
| Urbano, FJ | 1 |
| Cadet, JL | 1 |
| Bisagno, V | 1 |
| Garcia, VA | 1 |
| Souza de Freitas, B | 1 |
| Busato, SB | 1 |
| D'avila Portal, BC | 1 |
| Piazza, FC | 1 |
| Schröder, N | 1 |
| Zombeck, JA | 1 |
| Fey, EG | 1 |
| Lyng, GD | 1 |
| Sonis, ST | 1 |
| Fernandes, HA | 2 |
| Zanin, KA | 2 |
| Patti, Cde L | 1 |
| Lopes-Silva, LB | 1 |
| Bizerra, CS | 1 |
| Bittencourt, LR | 2 |
| Frussa-Filho, R | 2 |
| Ozsoy, S | 1 |
| Aydin, D | 1 |
| Ekici, F | 1 |
| Wadhwa, M | 1 |
| Sahu, S | 1 |
| Kumari, P | 1 |
| Kauser, H | 1 |
| Ray, K | 1 |
| Panjwani, U | 1 |
| Lee, H | 1 |
| Kim, KC | 1 |
| Cho, MS | 1 |
| Suh, SH | 1 |
| Hong, YM | 1 |
| Duchêne, A | 1 |
| Perier, M | 1 |
| Zhao, Y | 1 |
| Liu, X | 1 |
| Thomasson, J | 1 |
| Chauveau, F | 1 |
| Piérard, C | 1 |
| Lagarde, D | 1 |
| Picoli, C | 1 |
| Jeanson, T | 1 |
| Mouthon, F | 1 |
| Dauvilliers, Y | 2 |
| Giaume, C | 1 |
| Lin, JS | 2 |
| Charvériat, M | 1 |
| Zhang, LL | 1 |
| Liu, HQ | 1 |
| Yu, XH | 2 |
| Zhang, Y | 1 |
| Tian, JS | 1 |
| Song, XR | 1 |
| Han, B | 1 |
| Liu, AJ | 2 |
| Sagawa, Y | 1 |
| Sato, M | 1 |
| Sakai, N | 1 |
| Chikahisa, S | 1 |
| Chiba, S | 1 |
| Maruyama, T | 1 |
| Yamamoto, J | 1 |
| Nishino, S | 4 |
| Cohen, S | 1 |
| Ifergane, G | 1 |
| Vainer, E | 1 |
| Matar, MA | 1 |
| Kaplan, Z | 1 |
| Zohar, J | 1 |
| Mathé, AA | 1 |
| Cohen, H | 1 |
| Terada, J | 1 |
| Fukushi, I | 1 |
| Takeda, K | 1 |
| Hasebe, Y | 1 |
| Pokorski, M | 1 |
| Tatsumi, K | 1 |
| Okada, Y | 1 |
| Yates, CC | 2 |
| Charlesworth, A | 1 |
| Reese, NB | 2 |
| Ishida, K | 1 |
| Skinner, RD | 2 |
| Regenthal, R | 1 |
| Koch, H | 1 |
| Köhler, C | 1 |
| Preiss, R | 1 |
| Krügel, U | 1 |
| Fujiki, N | 2 |
| Cheng, T | 1 |
| Yoshino, F | 1 |
| Pallier, PN | 1 |
| Pedersen, CS | 1 |
| Goetghebeur, P | 1 |
| Dias, R | 2 |
| Reichel, CM | 1 |
| See, RE | 1 |
| Petit, JM | 1 |
| Tobler, I | 1 |
| Kopp, C | 1 |
| Morgenthaler, F | 1 |
| Borbély, AA | 1 |
| Magistretti, PJ | 1 |
| Okuro, M | 1 |
| Kotorii, N | 1 |
| Ishimaru, Y | 1 |
| Sokoloff, P | 1 |
| Moreira, KM | 1 |
| Ferreira, TL | 1 |
| Hipolide, DC | 1 |
| Fornari, RV | 1 |
| Oliveira, MG | 1 |
| Goetghebeur, PJ | 1 |
| Lerdrup, L | 1 |
| Sylvest, A | 1 |
| Dawson, N | 1 |
| Thompson, RJ | 1 |
| McVie, A | 1 |
| Thomson, DM | 1 |
| Morris, BJ | 1 |
| Pratt, JA | 1 |
| Garrison, MK | 1 |
| Ferraro, L | 1 |
| Antonelli, T | 1 |
| Beggiato, S | 1 |
| Cristina Tomasini, M | 1 |
| Fuxe, K | 1 |
| Tanganelli, S | 1 |
| Santamaria-Cano, J | 1 |
| Patti, CL | 1 |
| Wuo-Silva, R | 1 |
| Carvalho, RC | 1 |
| Fernandes-Santos, L | 1 |
| Mahler, SV | 1 |
| Hensley-Simon, M | 1 |
| Tahsili-Fahadan, P | 1 |
| LaLumiere, RT | 1 |
| Thomas, C | 1 |
| Fallon, RV | 1 |
| Kalivas, PW | 1 |
| Aston-Jones, G | 1 |
| Eagle, DM | 1 |
| Tufft, MR | 1 |
| Goodchild, HL | 1 |
| Cai, GJ | 1 |
| Chu, ZX | 1 |
| Su, DF | 1 |
| Chen, CR | 1 |
| Qu, WM | 1 |
| Qiu, MH | 1 |
| Xu, XH | 1 |
| Yao, MH | 1 |
| Urade, Y | 1 |
| Huang, ZL | 1 |
| van Vliet, SA | 2 |
| van Vlieta, SA | 1 |
| Blezer, EL | 1 |
| Jongsma, MJ | 2 |
| Vanwersch, RA | 2 |
| Olivier, B | 2 |
| Philippens, IH | 2 |
| Arnulf, I | 1 |
| Bastuji, H | 1 |
| Anaclet, C | 1 |
| Parmentier, R | 1 |
| Kocher, L | 1 |
| Yanagisawa, M | 2 |
| Lehert, P | 1 |
| Ligneau, X | 1 |
| Perrin, D | 1 |
| Robert, P | 1 |
| Roux, M | 1 |
| Lecomte, JM | 1 |
| Schwartz, JC | 1 |
| Chemelli, RM | 1 |
| Willie, JT | 1 |
| Sinton, CM | 1 |
| Elmquist, JK | 1 |
| Scammell, T | 1 |
| Lee, C | 1 |
| Richardson, JA | 1 |
| Williams, SC | 1 |
| Xiong, Y | 1 |
| Kisanuki, Y | 1 |
| Fitch, TE | 1 |
| Nakazato, M | 1 |
| Hammer, RE | 1 |
| Saper, CB | 1 |
| Wisor, JP | 1 |
| Sora, I | 1 |
| Uhl, GH | 1 |
| Mignot, E | 1 |
| Edgar, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Therapeutic Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation in Healthy Subjects[NCT03182413] | Phase 1 | 20 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| The Effect of Caffeine on the Narcoleptic Patients Randomized Controlled Clinical Trial[NCT02832336] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2016-10-01 | Completed | ||
| A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea[NCT02494102] | Phase 4 | 105 participants (Actual) | Interventional | 2016-02-29 | Terminated | ||
| Modafinil Treatment for Sleep/Wake Disturbances in Older Adults[NCT00626210] | Phase 4 | 2 participants (Actual) | Interventional | 2008-02-29 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of time of above compared between groups (NCT02494102)
Timeframe: 24 hours
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 53.5 |
| Modafinil | 61.0 |
Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome. (NCT02494102)
Timeframe: baseline and 6 hours after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -5.67 |
| Modafinil | -8.91 |
(NCT00626210)
Timeframe: 1 month
| Intervention | hours (Median) |
|---|---|
| Modafinil | 9.5 |
2 reviews available for modafinil and Disease Models, Animal
| Article | Year |
|---|---|
The vigilance promoting drug modafinil modulates serotonin transmission in the rat prefrontal cortex and dorsal raphe nucleus. Possible relevance for its postulated antidepressant activity.
Topics: Animals; Antidepressive Agents; Benzhydryl Compounds; Disease Models, Animal; Dopamine; Humans; Ment | 2013 |
[Diagnostic and therapeutic update in narcolepsy].
Topics: Adolescent; Adult; Age of Onset; Animals; Autoimmune Diseases; Benzhydryl Compounds; Cataplexy; Chil | 2012 |
2 trials available for modafinil and Disease Models, Animal
| Article | Year |
|---|---|
Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA.
Topics: Animals; Anxiety; Cognition; Disease Models, Animal; Disorders of Excessive Somnolence; Male; Mice; | 2023 |
An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Disease Models, Animal; Female; Hi | 2008 |
47 other studies available for modafinil and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Modafinil attenuates the neuroinflammatory response after experimental traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Caspase 3; Disease Models, Animal; Inf | 2023 |
Recovery Mimicking "Ideal" CPAP Adherence Does Not Improve Wakefulness or Cognition in Chronic Murine Models of OSA: Effect of Wake-Promoting Agents.
Topics: Animals; Cognition; Continuous Positive Airway Pressure; Disease Models, Animal; Disorders of Excess | 2023 |
Therapeutic effects of modafinil in ischemic stroke; possible role of NF-κB downregulation.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Brain Ischemia; Disease Models, Animal; Down-Re | 2019 |
Repeated restraint stress potentiates methylphenidate and modafinil-induced behavioral sensitization in rats.
Topics: Adaptation, Psychological; Animals; Behavior, Animal; Central Nervous System Stimulants; Disease Mod | 2020 |
Biochemical and histopathological evidence for the beneficial effects of modafinil on the rat model of inflammatory bowel disease: involvement of nitric oxide pathway.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Colitis; Disease Models, Animal; Dose-Response Relat | 2020 |
Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington's Disease.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ele | 2020 |
Mesenchymal stem cells with modafinil (gold nanoparticles) significantly improves neurological deficits in rats after middle cerebral artery occlusion.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Gold; Humans; Infarction, Middle Cerebral Artery; M | 2020 |
The wake-promoting drug Modafinil prevents motor impairment in sickness behavior induced by LPS in mice: Role for dopaminergic D1 receptor.
Topics: Animals; Anxiety; Benzazepines; Benzhydryl Compounds; Brain; Cell Movement; Depression; Disease Mode | 2018 |
Modafinil attenuates inflammation via inhibiting Akt/NF-κB pathway in apoE-deficient mouse model of atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Benzhydryl Compounds; Cell Pr | 2018 |
Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Arousal; Benzhydryl Compounds; Biogenic Monoamines; Disease Models, A | 2018 |
Prenatal exposure to modafinil alters locomotor behaviour and leucocyte phagocytosis in mice.
Topics: Age Factors; Animals; Disease Models, Animal; Female; Gestational Age; Leukocytes; Locomotion; Lumin | 2018 |
Continuous performance test impairment in a 22q11.2 microdeletion mouse model: improvement by amphetamine.
Topics: Amphetamine; Animals; Attention; Behavior, Animal; Central Nervous System Stimulants; Cognitive Dysf | 2018 |
Modafinil reduces amphetamine preference and prevents anxiety-like symptoms during drug withdrawal in young rats: Involvement of dopaminergic targets in VTA and striatum.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Anxiety; Central Nervous System Stimulants; Cor | 2019 |
HDAC superfamily promoters acetylation is differentially regulated by modafinil and methamphetamine in the mouse medial prefrontal cortex.
Topics: Acetylation; Animals; Central Nervous System Stimulants; Disease Models, Animal; Histone Deacetylase | 2020 |
Differential effects of modafinil on memory in naïve and memory-impaired rats.
Topics: Analysis of Variance; Animals; Animals, Newborn; Avoidance Learning; Benzhydryl Compounds; Disease M | 2013 |
A clinically translatable mouse model for chemotherapy-related fatigue.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Benzhydryl Compounds; Disease Models, Animal; Doxo | 2013 |
Effects of post-training modafinil administration in a discriminative avoidance task in mice.
Topics: Animals; Anxiety; Avoidance Learning; Benzhydryl Compounds; Discrimination Learning; Disease Models, | 2015 |
Effects of modafinil on pentylenetetrazol-induced convulsive epilepsy.
Topics: Animals; Anticonvulsants; Benzhydryl Compounds; Brain; Disease Models, Animal; Dose-Response Relatio | 2015 |
Caffeine and modafinil given during 48 h sleep deprivation modulate object recognition memory and synaptic proteins in the hippocampus of the rat.
Topics: Animals; Benzhydryl Compounds; Caffeine; Disease Models, Animal; Disks Large Homolog 4 Protein; Drug | 2015 |
Modafinil improves monocrotaline-induced pulmonary hypertension rat model.
Topics: Animals; Benzhydryl Compounds; Body Weight; Cyclic AMP; Disease Models, Animal; Endothelin-1; Gene E | 2016 |
Impact of Astroglial Connexins on Modafinil Pharmacological Properties.
Topics: Animals; Astrocytes; Benzhydryl Compounds; Connexin 30; Connexin 43; Connexins; Disease Models, Anim | 2016 |
The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness.
Topics: Analysis of Variance; Animals; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Ch | 2016 |
Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin/orexin deficient narcoleptic mice.
Topics: Animals; Ataxin-3; Benzhydryl Compounds; Body Temperature; Disease Models, Animal; Electroencephalog | 2016 |
The wake-promoting drug modafinil stimulates specific hypothalamic circuits to promote adaptive stress responses in an animal model of PTSD.
Topics: Adaptation, Psychological; Animals; Arousal; Benzhydryl Compounds; Corticosterone; Disease Models, A | 2016 |
Disharmony between wake- and respiration-promoting activities: effects of modafinil on ventilatory control in rodents.
Topics: Activity Cycles; Animals; Behavior, Animal; Benzhydryl Compounds; Disease Models, Animal; Hypercapni | 2016 |
Modafinil normalized hyperreflexia after spinal transection in adult rats.
Topics: Animals; Benzhydryl Compounds; Biophysical Phenomena; Connexins; Disease Models, Animal; Electric St | 2009 |
Depression-like deficits in rats improved by subchronic modafinil.
Topics: Animals; Antidepressive Agents; Attention; Behavior, Animal; Benzhydryl Compounds; Central Nervous S | 2009 |
Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Ataxin-3; Benzhydryl Compounds; Cen | 2009 |
Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease.
Topics: Affect; Alprazolam; Animals; Benzhydryl Compounds; Body Weight; Central Nervous System Stimulants; C | 2009 |
Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.
Topics: Animals; Antipsychotic Agents; Attention; Behavior, Animal; Behavioral Sciences; Benzhydryl Compound | 2009 |
Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse.
Topics: Amphetamine-Related Disorders; Animals; Behavior, Addictive; Benzhydryl Compounds; Disease Models, A | 2010 |
Metabolic response of the cerebral cortex following gentle sleep deprivation and modafinil administration.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Cerebral Cortex; Disease Models, A | 2010 |
Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice.
Topics: Animals; Ataxin-3; Benzhydryl Compounds; Body Temperature; Caffeine; Central Nervous System Stimulan | 2010 |
Modafinil prevents inhibitory avoidance memory deficit induced by sleep deprivation in rats.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzhydryl Compounds; Disease M | 2010 |
Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model.
Topics: Animals; Antipsychotic Agents; Attention; Behavior, Animal; Benzhydryl Compounds; Discrimination, Ps | 2010 |
Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity.
Topics: Animals; Autoradiography; Behavior, Animal; Benzhydryl Compounds; Brain; Central Nervous System Stim | 2012 |
Wind-up of stretch reflexes as a measure of spasticity in chronic spinalized rats: The effects of passive exercise and modafinil.
Topics: Analysis of Variance; Animals; Benzhydryl Compounds; Chronic Disease; Disease Models, Animal; Electr | 2011 |
Inhibitory effects of modafinil on emotional memory in mice.
Topics: Amnesia; Animals; Avoidance Learning; Behavior, Animal; Benzhydryl Compounds; Central Nervous System | 2013 |
Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors.
Topics: Amino Acid Transport System y+; Amino Acids; Analysis of Variance; Animals; Benzhydryl Compounds; Co | 2014 |
Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Benzhydryl Compounds; Cent | 2007 |
A novel animal model for motion sickness and its first application in rodents.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Defecation; Disease Models, Animal | 2007 |
Modafinil exerts a dose-dependent antiepileptic effect mediated by adrenergic alpha1 and histaminergic H1 receptors in mice.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Electroencephalography; Electroshock; Epileps | 2007 |
Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Benzhydryl Compounds; Biomarke | 2008 |
Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Callithrix; Disease Models, A | 2008 |
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
Topics: Age of Onset; Animals; Benzhydryl Compounds; Carrier Proteins; Disease Models, Animal; Dog Diseases; | 1999 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |